Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus Gemcitabine in Pancreatic Cancer
NCT00267020Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enzastaurin in pancreatic cancer (PC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival at 27.7 months. Started Dec 2005; status: completed.
02
Drugs
enzastaurin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00267020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267020.